Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback